Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
Identifieur interne : 002A21 ( Main/Exploration ); précédent : 002A20; suivant : 002A22Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
Auteurs : RBID : pubmed:16595488English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Female, Fluorine Radioisotopes, Fructose (analogs & derivatives), Fructose (diagnostic use), Fructose (pharmacokinetics), Humans, Indium Radioisotopes, Male, Middle Aged, Neoplasms (metabolism), Neoplasms (radionuclide imaging), Octreotide (analogs & derivatives), Octreotide (diagnostic use), Octreotide (pharmacokinetics), Pentetic Acid (analogs & derivatives), Pentetic Acid (diagnostic use), Pentetic Acid (pharmacokinetics), Peptides, Cyclic (diagnostic use), Peptides, Cyclic (pharmacokinetics), Positron-Emission Tomography, Radiopharmaceuticals (diagnostic use), Radiopharmaceuticals (pharmacokinetics), Receptors, Somatostatin (metabolism), Tissue Distribution, Whole Body Imaging.
- MESH :
- chemical , analogs & derivatives : Fructose, Octreotide, Pentetic Acid.
- chemical , diagnostic use : Fructose, Octreotide, Pentetic Acid, Peptides, Cyclic, Radiopharmaceuticals.
- chemical , metabolism : Receptors, Somatostatin.
- chemical , pharmacokinetics : Fructose, Octreotide, Pentetic Acid, Peptides, Cyclic, Radiopharmaceuticals.
- chemical : Fluorine Radioisotopes, Indium Radioisotopes.
- metabolism : Neoplasms.
- radionuclide imaging : Neoplasms.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Positron-Emission Tomography, Tissue Distribution, Whole Body Imaging.
Abstract
A recently developed (18)F-labeled PET tracer for somatostatin receptor (sstr) imaging, N(alpha)-(1-deoxy-D-fructosyl)-N(epsilon)-(2-[(18)F]fluoropropionyl)-Lys(0)-Tyr(3)-octreotate (Gluc-Lys([(18)F]FP)-TOCA), was evaluated in patients with sstr-positive tumors by assessing the pharmacokinetics, biodistribution, and diagnostic performance in comparison with [(111)In]DTPA-octreotide.
PubMed: 16595488
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.</title><author><name sortKey="Meisetschl Ger, G Nther" uniqKey="Meisetschl Ger G">Günther Meisetschläger</name><affiliation wicri:level="3"><nlm:affiliation>Department of Nuclear Medicine, Technische Universität München, München, Germany. g.meisetschlager@lrz.tum.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Nuclear Medicine, Technische Universität München, München</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Poethko, Thorsten" uniqKey="Poethko T">Thorsten Poethko</name></author><author><name sortKey="Stahl, Alexander" uniqKey="Stahl A">Alexander Stahl</name></author><author><name sortKey="Wolf, Ingo" uniqKey="Wolf I">Ingo Wolf</name></author><author><name sortKey="Scheidhauer, Klemens" uniqKey="Scheidhauer K">Klemens Scheidhauer</name></author><author><name sortKey="Schottelius, Margret" uniqKey="Schottelius M">Margret Schottelius</name></author><author><name sortKey="Herz, Michael" uniqKey="Herz M">Michael Herz</name></author><author><name sortKey="Wester, Hans J" uniqKey="Wester H">Hans J Wester</name></author><author><name sortKey="Schwaiger, Markus" uniqKey="Schwaiger M">Markus Schwaiger</name></author></titleStmt><publicationStmt><date when="2006">2006</date><idno type="RBID">pubmed:16595488</idno><idno type="pmid">16595488</idno><idno type="wicri:Area/Main/Corpus">002C03</idno><idno type="wicri:Area/Main/Curation">002C03</idno><idno type="wicri:Area/Main/Exploration">002A21</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Fluorine Radioisotopes</term><term>Fructose (analogs & derivatives)</term><term>Fructose (diagnostic use)</term><term>Fructose (pharmacokinetics)</term><term>Humans</term><term>Indium Radioisotopes</term><term>Male</term><term>Middle Aged</term><term>Neoplasms (metabolism)</term><term>Neoplasms (radionuclide imaging)</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (diagnostic use)</term><term>Octreotide (pharmacokinetics)</term><term>Pentetic Acid (analogs & derivatives)</term><term>Pentetic Acid (diagnostic use)</term><term>Pentetic Acid (pharmacokinetics)</term><term>Peptides, Cyclic (diagnostic use)</term><term>Peptides, Cyclic (pharmacokinetics)</term><term>Positron-Emission Tomography</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Radiopharmaceuticals (pharmacokinetics)</term><term>Receptors, Somatostatin (metabolism)</term><term>Tissue Distribution</term><term>Whole Body Imaging</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Fructose</term><term>Octreotide</term><term>Pentetic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Fructose</term><term>Octreotide</term><term>Pentetic Acid</term><term>Peptides, Cyclic</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Fructose</term><term>Octreotide</term><term>Pentetic Acid</term><term>Peptides, Cyclic</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Fluorine Radioisotopes</term><term>Indium Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Positron-Emission Tomography</term><term>Tissue Distribution</term><term>Whole Body Imaging</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A recently developed (18)F-labeled PET tracer for somatostatin receptor (sstr) imaging, N(alpha)-(1-deoxy-D-fructosyl)-N(epsilon)-(2-[(18)F]fluoropropionyl)-Lys(0)-Tyr(3)-octreotate (Gluc-Lys([(18)F]FP)-TOCA), was evaluated in patients with sstr-positive tumors by assessing the pharmacokinetics, biodistribution, and diagnostic performance in comparison with [(111)In]DTPA-octreotide.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16595488</PMID><DateCreated><Year>2006</Year><Month>04</Month><Day>05</Day></DateCreated><DateCompleted><Year>2006</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0161-5505</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J. Nucl. Med.</ISOAbbreviation></Journal><ArticleTitle>Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.</ArticleTitle><Pagination><MedlinePgn>566-73</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">A recently developed (18)F-labeled PET tracer for somatostatin receptor (sstr) imaging, N(alpha)-(1-deoxy-D-fructosyl)-N(epsilon)-(2-[(18)F]fluoropropionyl)-Lys(0)-Tyr(3)-octreotate (Gluc-Lys([(18)F]FP)-TOCA), was evaluated in patients with sstr-positive tumors by assessing the pharmacokinetics, biodistribution, and diagnostic performance in comparison with [(111)In]DTPA-octreotide.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-five patients with different sstr-positive tumors were included in the study and were injected with 105 +/- 50 MBq Gluc-Lys([(18)F]FP)-TOCA. PET was performed up to 120 min with 2 different dynamic imaging protocols. Tracer kinetics in tumors and nontumor tissues and tumor-to-background ratios were described by region-of-interest analysis and standardized uptake values (SUVs). In 16 patients, sstr scintigraphy with [(111)In]DTPA-octreotide was performed (whole-body scans and SPECT). Two independent experts on PET and gamma- camera scans performed lesion counts.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Gluc-Lys([(18)F]FP)-TOCA showed a fast and intense tumor accumulation as well as a rapid clearance from blood serum (biexponential elimination, with the half-lives of the initial and the terminal elimination phase calculated as t(1/2)(1) = 2.3 +/- 1.3 min and t(1/2)(2) = 26.4 +/- 14.6 min, respectively). Tumor-to-background ratios at 16 +/- 9 min and 34 +/- 12 min were as high as 80% and 90% (% of maximum ratios), respectively. Tumors showed high SUVs ranging from 13.7 +/- 2.3 (tumors in lung) up to 26.9 +/- 15.4 (abdominal tumors). Tracer distribution within tumor and nontumor tissues was stable up to 120 min (except spleen). No significant bowel activity was observed. Comparison of 29 tumors located in the liver showed a mean tumor-to-background ratio of 5.3 +/- 2.6 for Gluc-Lys([(18)F]FP)-TOCA vs. 4.6 +/- 3.3 for [(111)In]DTPA-octreotide (P = 0.24). Visual image analysis revealed a significantly higher number of lesions (factor of 2.4) and improved interobserver correlation (r = 0.99 vs. 0.86) for PET.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Gluc-Lys([(18)F]FP)-TOCA PET allows a fast, high- contrast imaging of sstr-positive tumors. The biokinetics and diagnostic performance of Gluc-Lys([(18)F]FP)-TOCA are superior to [(111)In]DTPA-octreotide and-as far as can be derived from the literature-comparable with [(68)Ga]-DOTA-d Phe(1)-Tyr(3)-octreotide ([(68)Ga]DOTATOC).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meisetschläger</LastName><ForeName>Günther</ForeName><Initials>G</Initials><Affiliation>Department of Nuclear Medicine, Technische Universität München, München, Germany. g.meisetschlager@lrz.tum.de</Affiliation></Author><Author ValidYN="Y"><LastName>Poethko</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Stahl</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Ingo</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Scheidhauer</LastName><ForeName>Klemens</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Schottelius</LastName><ForeName>Margret</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Herz</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wester</LastName><ForeName>Hans J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Schwaiger</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Comparative Study</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>111In-octreotide, DTPA(0)-</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>N(alpha)-(1-deoxy- D-fructosyl)- N(epsilon)-(2-fluoropropionyl)-Lys(0)-Tyr(3)-octreotate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Peptides, Cyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>30237-26-4</RegistryNumber><NameOfSubstance>Fructose</NameOfSubstance></Chemical><Chemical><RegistryNumber>7A314HQM0I</RegistryNumber><NameOfSubstance>Pentetic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Fructose</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pentetic Acid</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Peptides, Cyclic</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Whole Body Imaging</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">47/4/566</ArticleId><ArticleId IdType="pubmed">16595488</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002A21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16595488
|texte= Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16595488" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |